Literature DB >> 11321427

Dysfunction of microvascular endothelial cells induced by tumor necrosis factor (TNFalpha): cellular and molecular mechanism.

H M Jin1, Q H Liu, X Cao, Z H Wu, G P Zhang, M Zhang, Z Y Sha.   

Abstract

The dysfunction of rat pulmonary microvascular endothelial cells (RPMVEC) induced by tumor necrosis factor alpha (TNFalpha) was investigated in cell culture. The TNFalpha concentrations added into culture were 1000-5000 u/ml. The study was done at different steps as follows: (1) cell proliferation dynamic, (2) coagulation and anti-coagulation, (3) adhesive molecule, (4) nitric oxide (NO), (5) oncogens, and (6) apoptosis. It was concluded that attention should be paid to the metabolic disorder and dysfunction of RPMVEC induced by TNFalpha which can not be found easily according to the morphological changes. This might be the common pathway in the pathogenesis of some diseases related to TNFalpha.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11321427

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  3 in total

1.  Markers of Islet Endothelial Dysfunction Occur in Male B6.BKS(D)-Leprdb/J Mice and May Contribute to Reduced Insulin Release.

Authors:  Meghan F Hogan; Amy W Liu; Michael J Peters; Joshua R Willard; Zaheen Rabbani; Erik C Bartholomew; Adam Ottley; Rebecca L Hull
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

2.  Nitric oxide suppression of cellular proliferation depends on cationic amino acid transporter activity in cytokine-stimulated pulmonary endothelial cells.

Authors:  Louis G Chicoine; Louis G Chicione; Michael R Stenger; Hongmei Cui; Andrea Calvert; Rebecca J Evans; B Keith English; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-01-14       Impact factor: 5.464

3.  An integrated pathway interaction network for the combination of four effective compounds from ShengMai preparations in the treatment of cardio-cerebral ischemic diseases.

Authors:  Fang Li; Yan-ni Lv; Yi-sha Tan; Kai Shen; Ke-feng Zhai; Hong-Lin Chen; Jun-ping Kou; Bo-yang Yu
Journal:  Acta Pharmacol Sin       Date:  2015-10-12       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.